摘要
嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法是二十一世纪的突破性疗法,主要用于治疗包括淋巴瘤和白血病在内的不同恶性肿瘤。过度的心肌纤维化是各种形式的心脏病和心力衰竭进展的一个重要因素。然而,针对纤维化的临床干预和治疗仍然有限。虽然目前没有直接治疗心肌纤维化的疗法,但最近的一项研究已经展示了一种潜在的新策略,即采用CAR-T细胞进行工程改造从而特异性地消融活化的成纤维细胞以显著改善心肌纤维化并改善心脏功能。本文综述了目前CAR-T细胞治疗心肌纤维化的现况及CAR-T细胞疗法技术优化和应用的前景。
Chimeric antigen receptor(CAR)-T cell therapy stands as a breakthrough therapy in the 21st century,which is mainly used to treat different malignant tumors including lymphoma and leukemia.Excessive myocardial fibrosis is an important factor in the progression of all forms of heart disease and heart failure.However,clinical interventions and treatments for fibrosis remain limited.Despite the current absence of a direct therapeutic regimen for myocardial fibrosis,a recent investigation has unveiled a potential novel approach in the realm of engineering CAR-T cells,tailored to specifically ablate activated fibroblasts,thereby yielding a notable amelioration in myocardial fibrosis and cardiac functionality.In this paper,the present status of the treatment of myocardial fibrosis with CAR-T cells and the prospect of optimization and application of CAR-T cell therapy are reviewed.
作者
付方方
陈欣
邢璐宇
FU Fangfang;CHEN Xin;XING Luyu(Clinical Medical College of Tianjin Medical University,Tianjin,300070,China;Department of Cardiology,Tianjin First Central Hospital)
出处
《临床心血管病杂志》
CAS
北大核心
2023年第9期734-737,共4页
Journal of Clinical Cardiology
关键词
免疫治疗
嵌合抗原受体T细胞
心肌纤维化
immunotherapy
chimeric antigen receptor T-cell
myocardial fibrosis